

Click on the link below to be directed to study information at "ClinicalTrials.Gov" the US National Institutes of Health website.

Condition		Active Research Studies	St. Luke's Contact
<u>ANATOMICAL SITE</u>	<u>RESEARCH BASE &amp; REFERENCE #</u>	<u>STUDY TITLE</u>	<u>ST. LUKE'S CONTACT</u>
<u>MDS</u>	NHLBI-MDS NCT02775383	<a href="#">The National Myelodysplastic Syndromes Natural History Study</a>	Karley, 218-249-5002 <a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a>
<u>BREAST</u>	Alliance A011202 NCT01901094	<a href="#">A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy</a>	Karley, 218-249-5002 <a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a>
<u>BREAST</u>	Alliance A011502 NCT02927249	<a href="#">A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial</a>	Karley, 218-249-5002 <a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a>
<u>BREAST</u>	SWOG S1207 NCT01674140	<a href="#">Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of EVEROLIMUS in Patients with High-Risk, Hormone Receptor-Positive AND HER2/neu Negative Breast Cancer.</a>	Karley, 218-249-5002 <a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a>
<u>BREAST</u>	NRG-BR002 NCT02364557	<a href="#">A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer</a>	Karley, 218-249-5002 <a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a>
<u>BREAST Medication-related Muscle Pain</u>	CTSU E1Z11 NCT01824836	<a href="#">A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)</a>	Karley, 218-249-5002 <a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a>
<u>LUNG Small Cell Lung Cancer</u>	NRG-CC003 NCT02635009	<a href="#">Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer</a>	Karley, 218-249-5002 <a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a>
<u>LUNG NSCLC</u>	NRG-LU002 NCT03137771	<a href="#">Maintenance Systemic Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial</a>	Karley, 218-249-5002 <a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a>

<u>LUNG NSCLC</u>	Alliance A151216 NCT02194738	<a href="#">Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)</a>	Karley, 218-249-5002 <a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a>
<u>NSCLC</u>	Alliance A081105 NCT02193282	<a href="#">Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)</a>	Karley, 218-249-5002 <a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a>
<u>NSCLC</u>	CTSU E4512 NCT02201992	<a href="#">A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein</a>	Karley, 218-249-5002 <a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a>
<u>NSCLC</u>	CTSU EA5142 NCT02595944	<a href="#">Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers</a>	Karley, 218-249-5002 <a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a>
<u>NSCLC</u>	ARMO Cypress-2 NCT03382912	<a href="#">A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1</a>	Lisa RN, 218-249-2567 <a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a>
<u>PANCREAS</u>	Boston Biomedical CanSTEM111p NCT02993731	<a href="#">A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma</a>	Anne RN, 218-249-5581 <a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a>
<u>BLADDER</u>	SWOG S1605 NCT02844816	<a href="#">Phase II Trial of Atezolizumab in BCG-Unresponsive Non-muscle Invasive Bladder Cancer</a>	Karley, 218-249-5002 <a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a>
<u>PROSTATE</u> Intermediate-Risk, High-Risk	RTOG 0924 NCT01368588	<a href="#">Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial</a>	Karley, 218-249-5002 <a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a>
<u>COLORECTAL</u>	AbbVie M14-064 NCT03368859	<a href="#">Phase 2 Study Comparing Efficacy and Safety of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine/Oxaliplatin and Bevacizumab</a>	Lisa RN, 218-249-2567 <a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a>
<u>RECTAL</u>	NRG-GI002 NCT02921256	<a href="#">A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer</a>	Karley, 218-249-5002 <a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a>